# A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form

Study · id `cardio:ct-nct06540352` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06540352](<https://clinicaltrials.gov/study/NCT06540352>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06540352

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 175 participants.

## Technical summary

Registry record NCT06540352. Randomized; quadruple masking; primary purpose treatment. Start 2024-06-03 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 175 participants (enrolled count; ClinicalTrials.gov record NCT06540352, source copy `cardio:ctgov-nct06540352-2026-04-08`, retrieved 2026-10-26)
- Started: 2024-06-03 (actual) (ClinicalTrials.gov record NCT06540352, source copy `cardio:ctgov-nct06540352-2026-04-08`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06540352, source copy `cardio:ctgov-nct06540352-2026-04-08`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06540352, source copy `cardio:ctgov-nct06540352-2026-04-08`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT06540352, source copy `cardio:ctgov-nct06540352-2026-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06540352-2026-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
- Condition: Atrial Fibrillation
- Condition: Atrial Flutter
- Intervention (Drug): 4-Nitro-N-\[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl\]benzamide hydrochloride
- Intervention (Drug): Mannitol
- Lead sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Atrial flutter (`cardio:atrial-flutter`)
- Registry lists this organization as the lead sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation (`cardio:org-national-medical-research-center-for-cardiology-ministry-of-62fee0`)

## Provenance

Content hash: 9d6316978836e5a68718a9184ab2028ccfcd95ce5d35df3840ced5fe889e2ddc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
